Hyperhomocysteinemia and Endothelial Dysfunction.
TLDR
Six mechanisms have been suggested explaining HHcy-induced endothelial dysfunction and the goal of this review is to elaborate these mechanisms and to discuss biological and molecular events related to HHCy-induced ED.Abstract:
Hyperhomocysteinemia (HHcy) is a significant and independent risk factor for cardiovascular diseases. Endothelial dysfunction (ED) is the earliest indicator of atherosclerosis and vascular diseases. We and others have shown that HHcy induced ED in human and in animal models of HHcy induced by either high-methionine load or genetic deficiency. Six mechanisms have been suggested explaining HHcy-induced ED. These include 1) nitric oxide inhibition, 2) prostanoids regulation, 3) endothelium-derived hyperpolarizing factors suppression, 4) angiotensin II receptor-1 activation, 5) endothelin-1 induction, and 6) oxidative stress. The goal of this review is to elaborate these mechanisms and to discuss biological and molecular events related to HHcy-induced ED.read more
Citations
More filters
Journal ArticleDOI
Homocysteine-Induced Endothelial Dysfunction
TL;DR: This review discussed and in particular emphasis the potential cellular pathways and the biological processes involved that lead to homocysteine-induced endothelial dysfunction, in particular in the impaired endothelial dependent dilatation aspect.
Journal ArticleDOI
Circulating biologic markers of endothelial dysfunction in cerebral small vessel disease: A review.
Anna Poggesi,Marco Pasi,Francesca Pescini,Leonardo Pantoni,Domenico Inzitari,Domenico Inzitari +5 more
TL;DR: This review examines the main molecular factors involved in both endothelial function and dysfunction, and the evidence linking endothelial dysfunction with cerebral SVD, and gives an overview of clinical studies that have investigated the possible association between endothelial circulating biomarkers and SVD-related brain changes.
Journal ArticleDOI
Vascular endothelial dysfunction and pharmacological treatment.
TL;DR: Experimental and clinical studies have demonstrated that a variety of currently used or investigational drugs, such as angiotensin-converting enzyme inhibitors, ang Elliotensin AT1 receptors blockers, angiotENSin-(1-7), antioxidants, beta-blockers, calcium channel blockers, endothelial NO synthase enhancers, phosphodiesterase 5 inhibitors, sphingosine-1-phosphate and statins, exert endothelial protective effects.
Journal ArticleDOI
Immunosuppressive/anti-inflammatory cytokines directly and indirectly inhibit endothelial dysfunction--a novel mechanism for maintaining vascular function.
TL;DR: It is suggested that anti-inflammatory/immunosuppressive cytokines serve as novel therapeutic targets for inhibiting endothelial dysfunction, vascular inflammation and cardio- and cerebro-vascular diseases.
Journal ArticleDOI
Copper and homocysteine in cardiovascular diseases
TL;DR: A comprehensive understanding of Cu speciation and a development of selective modulation of Cu coordination to Cu-binding molecules to avoid Cu-Hcy complex formation would effectively improve the condition of cardiovascular disease.
References
More filters
Journal ArticleDOI
A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes
TL;DR: Higher folic acid intake by reducing tHcy levels promises to prevent arteriosclerotic vascular disease and under different assumptions, 13,500 to 50,000 CAD deaths annually could be avoided.
Journal Article
Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis.
TL;DR: Since the enzymatic abnormalities in both disorders share certain metabolic consequences, the conclusion has been reached that an elevated concentration of homocysteine, homocystine, or a derivative of hornocysteines is the common factor leading to arterial damage.
Journal ArticleDOI
Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen.
Jonathan S. Stamler,John A. Osborne,Omar Jaraki,LeRoy E. Rabbani,Mark E. Mullins,David J. Singel,Joseph Loscalzo +6 more
TL;DR: These results suggest that the normal endothelium modulates the potential, adverse effects of homocysteine by releasing EDRF and forming the adduct S-NO-homocysteines, a potent antiplatelet agent and vasodilator.
Journal ArticleDOI
EDHF: bringing the concepts together.
TL;DR: Several mechanisms have been proposed to link this pivotal step to the subsequent smooth muscle hyperpolarization and the main concepts are considered in detail in this review.
Journal ArticleDOI
Homocysteine Impairs the Nitric Oxide Synthase Pathway Role of Asymmetric Dimethylarginine
Markus Stühlinger,Philip S. Tsao,Jeng Horng Her,Masumi Kimoto,Robert F. Balint,John P. Cooke +5 more
TL;DR: Homocysteine post-translationally inhibits DDAH enzyme activity, causing ADMA to accumulate and inhibit nitric oxide synthesis, which may explain the known effect of homocysteines to impair endothelium-mediated nitricoxide–dependent vasodilatation.